MASTINI CRISTINA

Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD [10.1182/blood.2023021349]. Detail

Mastini, C., Campisi, M., Patrucco, E., Mura, G., Ferreira, A., Costa, C., et al. (2023). Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 15(702), 1-17 [10.1126/scitranslmed.abo3826]. Detail

Fontana, D., Crippa, V., Bassi, G., D'Aliberti, D., Mauri, M., Spinelli, S., et al. (2022). Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution. Intervento presentato a: 6° Annual Department Meeting of Medicine and Surgery 2022, Monza, Italy. Detail

Steidl, C., Aroldi, A., Mologni, L., Crespiatico, I., Fontana, D., Mastini, C., et al. (2022). Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience. LEUKEMIA RESEARCH, 118(July 2022) [10.1016/j.leukres.2022.106861]. Detail

Sharma, G., Arosio, G., Villa, M., Mauri, M., Zappa, M., Magistroni, V., et al. (2021). Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models. Intervento presentato a: AACR Annual Meeting, Philadelphia, PA [10.1158/1538-7445.AM2021-1113]. Detail